Skip to main content
Terug
NVS logo

Novartis AG

Datakwaliteit: 100%
NVS
NYSE Healthcare Drug Manufacturers - General
€ 148,09
▲ € 2,06 (1,41%)
Marktkapitalisatie: 286,27B
Ook genoteerd als NVSEF OTC
Dagbereik
€ 146,93 € 149,15
52-Weeksbereik
€ 97,72 € 170,46
Volume
1.563.123
50D / 200D Gem.
€ 154,83 / € 133,11
Vorige Slotkoers
€ 146,03

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E 20,4 0,4
P/B 6,2 2,9
ROE % 31,2 3,8
Net Margin % 25,6 3,9
Rev Growth 5Y % 5,7 10,0
D/E 0,8 0,2

Koersdoel Analisten

Hold
€ 127,00 -14.2%
Low: € 112,00 High: € 143,00
Forward K/W
16,8
Forward WPA
€ 8,81
WPA Groei (sch.)
+0,0%
Omzet Sch.
57 B

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 12,56
€ 12,04 – € 13,08
 69 B 6
FY2029 € 11,54
€ 11,06 – € 12,02
 66 B 6
FY2028 € 10,63
€ 10,19 – € 11,07
 64 B 7

Belangrijkste Punten

Revenue grew 5,66% annually over 5 years — modest growth
Earnings grew 17,71% over the past year
ROE of 31,17% indicates high profitability
Net margin of 25,64% shows strong profitability
Generating 17,69B in free cash flow
PEG of 0,85 suggests growth is underpriced

Groei

Revenue Growth (5Y)
5,66%
Revenue (1Y)5,97%
Earnings (1Y)17,71%
FCF Growth (3Y)22,92%

Kwaliteit

Return on Equity
31,17%
ROIC15,40%
Net Margin25,64%
Op. Margin31,15%

Veiligheid

Debt / Equity
0,80
Current Ratio1,12
Interest Coverage14,38

Waardering

P/E Ratio
20,37
P/B Ratio6,21
EV/EBITDA18,27
Dividend Yield0,03%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 5,97% Revenue Growth (3Y) 8,38%
Earnings Growth (1Y) 17,71% Earnings Growth (3Y) -2,71%
Revenue Growth (5Y) 5,66% Earnings Growth (5Y) -12,54%
Profitability
Revenue (TTM) 54,81B Net Income (TTM) 14,06B
ROE 31,17% ROA 12,16%
Gross Margin 75,02% Operating Margin 31,15%
Net Margin 25,64% Free Cash Flow (TTM) 17,69B
ROIC 15,40% FCF Growth (3Y) 22,92%
Safety
Debt / Equity 0,80 Current Ratio 1,12
Interest Coverage 14,38 Dividend Yield 0,03%
Valuation
P/E Ratio 20,37 P/B Ratio 6,21
P/S Ratio 5,22 PEG Ratio 0,85
EV/EBITDA 18,27 Dividend Yield 0,03%
Market Cap 286,27B Enterprise Value 311,87B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 54,81B 51,72B 46,66B 43,46B 43,97B
Net Income 14,06B 11,94B 14,85B 6,96B 24,02B
EPS (Diluted) 7,19 5,87 7,10 3,17 10,63
Gross Profit 41,12B 38,90B 34,19B 31,88B 32,24B
Operating Income 17,07B 14,54B 9,77B 7,95B 10,06B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 115,57B 102,25B 99,95B 117,45B 131,80B
Total Liabilities 69,02B 58,12B 53,20B 58,03B 63,97B
Shareholders' Equity 46,13B 44,05B 46,67B 59,34B 67,66B
Total Debt 37,03B 31,26B 26,35B 27,91B 31,03B
Cash & Equivalents 11,44B 11,46B 13,39B 7,52B 12,41B
Current Assets 30,46B 29,70B 30,48B 36,91B 45,72B
Current Liabilities 27,28B 28,69B 26,39B 28,66B 30,21B

Strategiescores

This stock passed the criteria for 3 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#301 of 1021
55
Custom Capital Light Compounder
#149 of 211
31
Growth + Value Growth at a Reasonable Price (Peter Lynch)
#255 of 325
38

Recente Activiteit

Ingestapt Cash Flow Compounder
Mar 24, 2026
Ingestapt Capital Light Compounder
Mar 24, 2026
Ingestapt Growth at a Reasonable Price (Peter Lynch)
Mar 24, 2026